TSPAN31

Summary

TSPAN31 (tetraspanin 31, HGNC:10539) is a protein-coding gene on chromosome 12q14.1, encoding Tetraspanin-31 (Q12999).

The protein encoded by this gene is a member of the transmembrane 4 superfamily, also known as the tetraspanin family. Most of these members are cell-surface proteins that are characterized by the presence of four hydrophobic domains. The proteins mediate signal transduction events that play a role in the regulation of cell development, activation, growth and motility. This encoded protein is thought to be involved in growth-related cellular processes. This gene is associated with tumorigenesis and osteosarcoma.

Source: NCBI Gene 6302 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 178 total
• MANE Select transcript: NM_005981

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:10539
Approved symbol	TSPAN31
Name	tetraspanin 31
Location	12q14.1
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000135452
Ensembl biotype	protein_coding
OMIM	181035
Entrez	6302

Gene structure

Transcript identifiers

Ensembl transcripts: 21 — 12 protein_coding, 4 protein_coding_CDS_not_defined, 3 retained_intron, 2 nonsense_mediated_decay

ENST00000257910, ENST00000546922, ENST00000546993, ENST00000547311, ENST00000547472, ENST00000547992, ENST00000548093, ENST00000548167, ENST00000549052, ENST00000550528, ENST00000550791, ENST00000552816, ENST00000553089, ENST00000553221, ENST00000870604, ENST00000870605, ENST00000870606, ENST00000870607, ENST00000918697, ENST00000918698, ENST00000958144

RefSeq mRNA: 3 — MANE Select: NM_005981 NM_001330168, NM_001330169, NM_005981

CCDS: CCDS86313, CCDS8952

Canonical transcript exons

ENST00000257910 — 6 exons

Exon	Start	End
ENSE00002335650	57747216	57750219
ENSE00002418202	57745039	57745217
ENSE00003555432	57746176	57746256
ENSE00003623414	57747018	57747131
ENSE00003683781	57745745	57745912
ENSE00003690163	57746589	57746720

Expression profiles

Bgee: expression breadth ubiquitous, 288 present calls, max score 97.62.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 22.7073 / max 1393.0810, expressed in 1800 samples.

FANTOM5 promoters (7 alternative TSS)

Promoter ID	TPM avg	Samples expressed
126321	22.5116	1800
126319	0.0733	21
126318	0.0546	34
126317	0.0271	8
126315	0.0253	6
126316	0.0102	4
206755	0.0052	1

Top tissues by expression

295 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
pancreatic ductal cell	CL:0002079	97.62	gold quality
islet of Langerhans	UBERON:0000006	96.72	gold quality
pericardium	UBERON:0002407	96.01	gold quality
right lobe of thyroid gland	UBERON:0001119	96.00	gold quality
right adrenal gland	UBERON:0001233	95.94	gold quality
corpus epididymis	UBERON:0004359	95.85	gold quality
endothelial cell	CL:0000115	95.76	gold quality
right adrenal gland cortex	UBERON:0035827	95.73	gold quality
renal medulla	UBERON:0000362	95.71	gold quality
gall bladder	UBERON:0002110	95.70	gold quality
trigeminal ganglion	UBERON:0001675	95.59	gold quality
thyroid gland	UBERON:0002046	95.48	gold quality
left lobe of thyroid gland	UBERON:0001120	95.47	gold quality
left adrenal gland	UBERON:0001234	95.44	gold quality
endocervix	UBERON:0000458	95.39	gold quality
adrenal cortex	UBERON:0001235	95.39	gold quality
descending thoracic aorta	UBERON:0002345	95.39	gold quality
left coronary artery	UBERON:0001626	95.36	gold quality
right coronary artery	UBERON:0001625	95.31	gold quality
coronary artery	UBERON:0001621	95.27	gold quality
left adrenal gland cortex	UBERON:0035825	95.27	gold quality
thoracic aorta	UBERON:0001515	95.21	gold quality
ascending aorta	UBERON:0001496	95.19	gold quality
right uterine tube	UBERON:0001302	95.06	gold quality
adrenal gland	UBERON:0002369	95.05	gold quality
right ovary	UBERON:0002118	95.04	gold quality
body of uterus	UBERON:0009853	94.94	gold quality
aorta	UBERON:0000947	94.91	gold quality
pons	UBERON:0000988	94.91	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	94.84	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-GEOD-84465	yes	2049.60
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 3)

• CDK4, MDM2, SAS and GLI genes are amplified in leiomyosarcoma, alveolar and embryonal rhabdomyosarcoma (PMID:15024701)
• TSPAN31 suppresses cell proliferation in human cervical cancer through down-regulation of its antisense pairing with CDK4. (PMID:32207169)
• Overexpression of Tetraspanin31 contributes to malignant potential and poor outcomes in gastric cancer. (PMID:35307915)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	tspan31	ENSDARG00000074554
mus_musculus	Tspan31	ENSMUSG00000006736
rattus_norvegicus	Tspan31	ENSRNOG00000025592

Paralogs (32): TSPAN6 (ENSG00000000003), CD9 (ENSG00000010278), TSPAN9 (ENSG00000011105), TSPAN17 (ENSG00000048140), TSPAN32 (ENSG00000064201), CD82 (ENSG00000085117), TSPAN15 (ENSG00000099282), CD37 (ENSG00000104894), UPK1A (ENSG00000105668), TSPAN12 (ENSG00000106025), TSPAN13 (ENSG00000106537), TSPAN14 (ENSG00000108219), CD81 (ENSG00000110651), TSPAN11 (ENSG00000110900), PRPH2 (ENSG00000112619), UPK1B (ENSG00000114638), TSPAN1 (ENSG00000117472), TSPAN8 (ENSG00000127324), TSPAN16 (ENSG00000130167), TSPAN2 (ENSG00000134198), CD63 (ENSG00000135404), TSPAN3 (ENSG00000140391), CD53 (ENSG00000143119), ROM1 (ENSG00000149489), TSPAN7 (ENSG00000156298), TSPAN18 (ENSG00000157570), TSPAN33 (ENSG00000158457), TSPAN5 (ENSG00000168785), CD151 (ENSG00000177697), TSPAN10 (ENSG00000182612), TSPAN4 (ENSG00000214063), TSPAN19 (ENSG00000231738)

Protein

Protein identifiers

Tetraspanin-31 — Q12999 (reviewed: Q12999)

Alternative names: Sarcoma-amplified sequence

All UniProt accessions (7): Q12999, F8VNT7, F8VP43, F8VS78, F8VVF8, F8VW54, F8VWE0

UniProt curated annotations — full annotation on UniProt →

Subcellular location. Membrane.

Similarity. Belongs to the tetraspanin (TM4SF) family.

RefSeq proteins (3): NP_001317097, NP_001317098, NP_005972* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000301	Tetraspanin_animals	Family
IPR018499	Tetraspanin/Peripherin	Family

Pfam: PF00335

UniProt features (14 total): topological domain 5, glycosylation site 4, transmembrane region 4, chain 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q12999-F1	89.29	0.64

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Glycosylation sites (4): 100, 109, 117, 134

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 168 (showing top): GSE45365_CD8A_DC_VS_CD11B_DC_IFNAR_KO_UP, GSE45365_HEALTHY_VS_MCMV_INFECTION_CD8_TCELL_IFNAR_KO_UP, STARK_PREFRONTAL_CORTEX_22Q11_DELETION_DN, BROWNE_HCMV_INFECTION_48HR_DN, ONKEN_UVEAL_MELANOMA_UP, KESHELAVA_MULTIPLE_DRUG_RESISTANCE, BLALOCK_ALZHEIMERS_DISEASE_UP, NIKOLSKY_BREAST_CANCER_12Q13_Q21_AMPLICON, TSENG_IRS1_TARGETS_DN, DOUGLAS_BMI1_TARGETS_DN, HOOI_ST7_TARGETS_DN, NRF2_01, SPIELMAN_LYMPHOBLAST_EUROPEAN_VS_ASIAN_DN, CETS1P54_01, YIH_RESPONSE_TO_ARSENITE_C3

GO Biological Process (1): positive regulation of cell population proliferation (GO:0008284)

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (2): plasma membrane (GO:0005886), membrane (GO:0016020)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cell population proliferation	1
regulation of cell population proliferation	1
positive regulation of cellular process	1
binding	1
membrane	1
cell periphery	1
cellular anatomical structure	1

Protein interactions and networks

STRING

522 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
TSPAN31	CD53	P19397	694
TSPAN31	CD37	P11049	688
TSPAN31	TSPAN17	Q96FV3	666
TSPAN31	TM4SF1	P30408	632
TSPAN31	METTL1	Q9UBP6	595
TSPAN31	CD63	P08962	588
TSPAN31	TSPAN5	P62079	567
TSPAN31	CD9	P21926	562
TSPAN31	CD81	P18582	556
TSPAN31	UPK1A	O00322	555
TSPAN31	OS9	Q13438	545
TSPAN31	FRS2	Q8WU20	531
TSPAN31	TSPAN1	O60635	506
TSPAN31	TSPAN8	P19075	504
TSPAN31	CDK4	P11802	500

IntAct

20 interactions, top by confidence:

A	B	Type	Score
SLC30A2	TSPAN31	psi-mi:“MI:0915”(physical association)	0.560
CYP4F2	TSPAN31	psi-mi:“MI:0915”(physical association)	0.560
CMTM5	TSPAN31	psi-mi:“MI:0915”(physical association)	0.560
TSPAN31	SLC30A2	psi-mi:“MI:0915”(physical association)	0.560
TSPAN31	NAT8	psi-mi:“MI:0915”(physical association)	0.560
TSPAN2	TSPAN31	psi-mi:“MI:0915”(physical association)	0.560
TSPAN31	CMTM5	psi-mi:“MI:0915”(physical association)	0.560
BMP10	TSPAN31	psi-mi:“MI:0915”(physical association)	0.560
TSPAN31	TMEM120B	psi-mi:“MI:0914”(association)	0.350
NAT8	TSPAN31	psi-mi:“MI:0915”(physical association)	0.000
TSPAN2	TSPAN31	psi-mi:“MI:0915”(physical association)	0.000
BMP10	TSPAN31	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (51): TSPAN31 (Two-hybrid), NAT8 (Two-hybrid), BMP10 (Two-hybrid), CMTM5 (Two-hybrid), TSPAN31 (Affinity Capture-RNA), XPO5 (Affinity Capture-MS), ALG3 (Affinity Capture-MS), NRM (Affinity Capture-MS), RHOBTB3 (Affinity Capture-MS), POMK (Affinity Capture-MS), CD81 (Affinity Capture-MS), MFSD1 (Affinity Capture-MS), ATP8 (Affinity Capture-MS), MFSD12 (Affinity Capture-MS), CD63 (Affinity Capture-MS)

ESM2 similar proteins: A0A8M2B5N2, A0A8V0ZLT4, A1L157, B5X3I6, F7BWT7, O15551, O19005, O35566, O95858, P11049, P31053, P35349, P40239, P40240, P40241, P48509, P61170, P61171, Q0VC33, Q12999, Q1JQA4, Q2KHY8, Q32KP1, Q3ZBH3, Q568Y5, Q5BJS2, Q5NCH9, Q5PRC1, Q5RAP8, Q5RH71, Q5U1V9, Q61470, Q63400, Q6GMK6, Q6GQF5, Q765N9, Q7ZUB3, Q80WR1, Q863I4, Q8BM86

Diamond homologs: O95857, Q12999, Q29257, Q32KP1, Q3ZBV0, Q5FVL6, Q5RAP8, Q5U1V9, Q5XHG6, Q7ZUB3, Q7ZWW7, Q9CQ88, Q9D8C2

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

178 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	89
Likely benign	24
Benign	13

Top pathogenic / likely-pathogenic (0)

SpliceAI

1475 predictions. Top by Δscore:

Variant	Effect	Δscore
12:57741909:TA:T	donor_loss	1.0000
12:57745743:AGCT:A	acceptor_gain	1.0000
12:57745744:GCTG:G	acceptor_gain	1.0000
12:57745838:G:GT	donor_gain	1.0000
12:57745925:G:GT	donor_gain	1.0000
12:57746587:A:AG	acceptor_gain	1.0000
12:57746588:G:GG	acceptor_gain	1.0000
12:57746588:GAC:G	acceptor_gain	1.0000
12:57746588:GACA:G	acceptor_gain	1.0000
12:57746650:G:GT	donor_gain	1.0000
12:57746718:GCA:G	donor_gain	1.0000
12:57746721:G:GG	donor_gain	1.0000
12:57747016:A:AG	acceptor_gain	1.0000
12:57747017:G:GG	acceptor_gain	1.0000
12:57749155:C:A	donor_gain	1.0000
12:57749452:A:AC	donor_gain	1.0000
12:57749453:C:CC	donor_gain	1.0000
12:57749453:CT:C	donor_gain	1.0000
12:57741910:A:AC	donor_gain	0.9900
12:57741911:C:CC	donor_gain	0.9900
12:57741911:CCT:C	donor_gain	0.9900
12:57745743:A:AG	acceptor_gain	0.9900
12:57745744:G:GG	acceptor_gain	0.9900
12:57745838:G:T	donor_gain	0.9900
12:57745931:A:AG	donor_gain	0.9900
12:57746174:A:AG	acceptor_gain	0.9900
12:57746175:G:GG	acceptor_gain	0.9900
12:57746583:TTTCA:T	acceptor_loss	0.9900
12:57746584:TTCA:T	acceptor_loss	0.9900
12:57746585:TCA:T	acceptor_loss	0.9900

AlphaMissense

1383 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
12:57747120:A:C	S183R	0.996
12:57747122:C:A	S183R	0.996
12:57747122:C:G	S183R	0.996
12:57745170:T:C	F6L	0.987
12:57745172:T:A	F6L	0.987
12:57745172:T:G	F6L	0.987
12:57747282:T:C	F209L	0.987
12:57747284:T:A	F209L	0.987
12:57747284:T:G	F209L	0.987
12:57745205:C:A	N17K	0.984
12:57745205:C:G	N17K	0.984
12:57745751:A:C	S24R	0.981
12:57745753:C:A	S24R	0.981
12:57745753:C:G	S24R	0.981
12:57747247:G:C	R197P	0.981
12:57747243:T:C	F196L	0.980
12:57747245:T:A	F196L	0.980
12:57747245:T:G	F196L	0.980
12:57746612:G:C	W112C	0.965
12:57746612:G:T	W112C	0.965
12:57747121:G:A	S183N	0.963
12:57747112:T:C	L180P	0.962
12:57747117:T:C	F182L	0.962
12:57747119:T:A	F182L	0.962
12:57747119:T:G	F182L	0.962
12:57747222:G:C	G189R	0.962
12:57745192:T:C	L13P	0.961
12:57745192:T:A	L13H	0.957
12:57747051:T:A	C160S	0.957
12:57747052:G:C	C160S	0.957

dbSNP variants (sampled 300 via entrez): RS1000416664 (12:57747962 G>A,C), RS1000870693 (12:57748322 C>G), RS1001155355 (12:57749593 T>C), RS1001436631 (12:57745546 C>A,T), RS1002207037 (12:57749098 C>A,T), RS1002653772 (12:57745505 T>C), RS1002924139 (12:57746101 C>G,T), RS1003208178 (12:57747486 G>A), RS1004516189 (12:57745587 C>T), RS1004656804 (12:57750297 G>A,T), RS1004724115 (12:57748846 C>T), RS1005006906 (12:57749964 T>C), RS1005319530 (12:57746941 T>C), RS1005616471 (12:57747406 A>G), RS1006511986 (12:57744719 A>C)

Disease associations

OMIM: gene MIM:181035 | disease phenotypes: MIM:609048, MIM:612219, MIM:167000

GenCC curated gene-disease

Mondo (5): hereditary neoplastic syndrome (MONDO:0015356), familial melanoma (MONDO:0018961), melanoma, cutaneous malignant, susceptibility to, 3 (MONDO:0012183), Ewing sarcoma (MONDO:0012817), ovarian cancer (MONDO:0008170)

Orphanet (5): Inherited cancer-predisposing syndrome (Orphanet:140162), Familial melanoma (Orphanet:618), OBSOLETE: Neuroepithelioma (Orphanet:2677), Skeletal Ewing sarcoma (Orphanet:319), Rare ovarian cancer (Orphanet:213500)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

MeSH disease descriptors (3)

Descriptor	Name	Tree numbers
D009386	Neoplastic Syndromes, Hereditary	C04.700; C16.320.700
D010051	Ovarian Neoplasms	C04.588.322.455; C12.050.351.500.056.630.705; C12.050.351.937.418.685; C12.100.250.056.630.705; C12.900.418.685; C19.344.410; C19.391.630.705
D012512	Sarcoma, Ewing	C04.557.450.565.575.650.800; C04.557.450.795.620.800

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

PharmGKB variants

1 variants.

Variant	Genes	Level	Score	#Clin annots	Drugs
rs2069502	AGAP2, CDK4, MARCHF9, TSPAN31	3	2.00	1	somatropin recombinant

CTD chemical–gene interactions

40 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	decreases expression, increases abundance, increases expression	4
cobaltous chloride	decreases expression	2
Cadmium	increases abundance, increases expression, decreases expression	2
Valproic Acid	increases expression	2
aristolochic acid I	decreases expression	1
GSK-J4	decreases expression	1
bisphenol A	affects cotreatment, increases expression	1
4-hydroxy-2-nonenal	decreases expression	1
2,3-bis(3’-hydroxybenzyl)butyrolactone	affects cotreatment, decreases expression	1
4-aminophenylarsenoxide	affects binding, decreases reaction	1
di-n-butylphosphoric acid	affects expression	1
CGP 52608	affects binding, increases reaction	1
monomethylarsonous acid	decreases expression	1
ICG 001	increases expression	1
abrine	increases expression	1
NSC 689534	increases expression, affects binding	1
(+)-JQ1 compound	increases expression	1
4-(4-((5-(4,5-dimethyl-2-nitrophenyl)-2-furanyl)methylene)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl)benzoic acid	increases expression	1
Resveratrol	affects cotreatment, decreases expression	1
Decitabine	affects expression	1
Arsenic Trioxide	affects binding, decreases reaction	1
Vorinostat	increases expression	1
Acetaminophen	increases expression	1
Air Pollutants	decreases expression, increases abundance	1
Arsenic	decreases expression, increases abundance	1
Calcitriol	increases expression, affects cotreatment	1
Cisplatin	affects expression	1
Copper	affects binding, increases expression	1
Coumestrol	affects cotreatment, decreases expression	1
Dexamethasone	increases expression, affects cotreatment	1

Clinical trials (associated diseases)

270 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT04854018	PHASE4	COMPLETED	Indo-cyanine Green (ICG) in Paediatric Oncology MIS
NCT00190697	PHASE4	COMPLETED	A Study of LY353381 (Arzoxifene) for Patients Who Benefitted From This Drug in Other Oncology Trials and Wished to Continue Treatment
NCT00277160	PHASE4	COMPLETED	A Study of Primary Prophylaxis With Neulasta (Pegfilgrastim) Versus Secondary Prophylaxis After Chemotherapy in Elderly Subjects (>/= 65 Years Old) With Cancer
NCT00727961	PHASE4	COMPLETED	A Study to Evaluate Efficacy and Tolerance of Caelyx in Patients With Epithelial Ovarian Cancer. (Study P04072)(COMPLETED)
NCT00740116	PHASE4	COMPLETED	Tranexamic Acid in Surgery of Advanced Ovarian Cancer
NCT00817479	PHASE4	COMPLETED	Tumor Gene Expression in Women With Ovarian Cancer
NCT01432015	PHASE4	COMPLETED	Fosaprepitant Versus Aprepitant in the Prevention of Chemotherapy Induced Nausea and Vomiting
NCT01706120	PHASE4	UNKNOWN	Study of Clinical and Biological Prognostic Factors in Patients With Ovarian Cancer Receiving Carboplatin +Paclitaxel With Bevacizumab
NCT01932125	PHASE4	COMPLETED	An Interventional Study of Avastin (Bevacizumab) in Patients With Advanced/Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer
NCT01953107	PHASE4	COMPLETED	Oral Iron vs. Placebo in Newly Diagnosed Gynecologic Oncology Patients Who Are Surgical Candidates.
NCT02035345	PHASE4	TERMINATED	Slowed Carboplatin Infusion for Ovarian Cancer Patients Receiving Carboplatin Re-Treatment
NCT02243059	PHASE4	WITHDRAWN	Magnetic Resonance Imaging for Lymph Node Staging in Ovarian Cancer
NCT03164980	PHASE4	TERMINATED	QoL-Comparison Between Trabectedin/PLD and Pt-based Therapy in Patients With Pt-sensitive Recurrent Ovarian Cancer
NCT03384511	PHASE4	COMPLETED	The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies.
NCT03543462	PHASE4	COMPLETED	Diaphragmatic Resection And Gynecological Ovarian Neoplasm
NCT03752216	PHASE4	COMPLETED	NIraparib and Quality of LifE is a Longitudinal Study Evaluating in Real Life the Tolerability of Niraparib.
NCT03858166	PHASE4	TERMINATED	Efficacy and Safety of PEG-rhG-CSF Secondary Prophylaxis vs. Therapeutic Administration in Patients With Ovarian Cancer
NCT04024254	PHASE4	COMPLETED	A Study of Serum Folate Levels in Patients Treated With Olaparib
NCT04330040	PHASE4	COMPLETED	Prospective Multicentre Phase-IV Clinical Trial of Olaparib in Indian Patients With Ovarian and Metastatic Breast Cancer
NCT04352439	PHASE4	COMPLETED	Aspirin for Prevention of Venous Thromboembolism Among Ovarian Cancer Patients Receiving Neoadjuvant Chemotherapy
NCT05187208	PHASE4	UNKNOWN	PARP Inhibitor Oral Maintenance in Low-Risk Ovarian Cancer
NCT05606692	PHASE4	RECRUITING	Influences of Propofol and Sevoflurane Anesthesia in Ovarian Cancer (Anesthetics)
NCT05926336	PHASE4	RECRUITING	The Effects of Using Different Anesthetics on the Prognosis of Primary Tumors and Its Mechanism of Action
NCT06412120	PHASE4	RECRUITING	Study Evaluating Safety, Tolerability, and Metabolism of Niraparib
NCT06871787	PHASE4	NOT_YET_RECRUITING	Near-Infrared Fluorescence Imaging With Indocyanine Green to Evaluate Bowel Anastomoses in Gynecologic Oncology Surgery
NCT06887933	PHASE4	NOT_YET_RECRUITING	A Trial to Evaluate the Safety of Niraparib Tablets in Adult Female Participants With Advanced or Relapsed Epithelial Ovarian Cancer
NCT07469202	PHASE4	NOT_YET_RECRUITING	CYTALUX Dose Extension Study
NCT00987636	PHASE3	COMPLETED	Study in Localized and Disseminated Ewing Sarcoma
NCT01734863	PHASE3	WITHDRAWN	Post-operative Radiotherapy in Poor Responders Ewing’s Sarcoma Patients
NCT02063022	PHASE3	COMPLETED	Efficacy of Dose Intensification in Patients With Non-metastatic Ewing Sarcoma
NCT02306161	PHASE3	ACTIVE_NOT_RECRUITING	Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma
NCT03495921	PHASE3	TERMINATED	A Trial For Participants With Ewing’s Sarcoma Treated With Vigil in Combination With Irinotecan and Temozolomide
NCT05328258	PHASE3	RECRUITING	Use of GnRHa During Chemotherapy for Fertility Protection
NCT00001806	PHASE3	COMPLETED	Methods in Education for Breast Cancer Genetics
NCT00002477	PHASE3	UNKNOWN	Adjuvant Chemotherapy Compared With Observation in Treating Patients With Resected Early Stage Ovarian Epithelial Cancer
NCT00002568	PHASE3	COMPLETED	Combination Chemotherapy With or Without Surgery in Treating Patients With Stage III Ovarian Epithelial Cancer
NCT00002641	PHASE3	COMPLETED	Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma
NCT00002717	PHASE3	COMPLETED	Paclitaxel and Cisplatin in Treating Patients With Stage III or Stage IV Ovarian Cancer or Primary Peritoneal Cancer
NCT00002764	PHASE3	COMPLETED	Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue Sarcoma
NCT00002819	PHASE3	TERMINATED	Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Persistent Ovarian Epithelial Cancer